Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/LIMN/vs peers

LIMNLiminatus Pharma, Inc.vs its industry peers

A metric-by-metric comparison of Liminatus Pharma, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.

Full peer comparison
Peers: same SEC industry
CompanyMarket capP/E (TTM)P/BP/SRevenue growth (YoY)Earnings growth (YoY)EBIT marginROEROICPiotroski F1y total returnDividend yield
LIMNLiminatus Pharma, Inc.This$169M#8—563.0x#13——-187.8%#13—-3395.2%#13-170.3%#3———
PALIPALISADE BIO, INC.$216M#11.9x#11.8x#7——-16.2%#6—-13.8%#3——-37.8%#5—
PLXProtalix BioTherapeutics, Inc.$209M#211.3x#22.9x#94.0x#5-1.2%#4-325.2%#14-10.4%#1-9.2%#2-12.3%#13#19.3%#3—
IKTInhibikase Therapeutics, Inc.$208M#3—1.4x#6—-100.0%#7-75.4%#11—-31.5%#6————
ARTVArtiva Biotherapeutics, Inc.$206M#4—0.6x#1—-100.0%#7-28.3%#7—-24.1%#4——12.0%#2—
DTILPRECISION BIOSCIENCES INC$194M#521.7x#33.7x#115.7x#6-50.1%#6-738.0%#15-152.2%#3-88.3%#11——-6.1%#4—
ACOGAlpha Cognition Inc.$180M#6—3.4x#1017.6x#7—-39.8%#10-221.7%#5-39.0%#8——44.0%#1—
IVVDInvivyd, Inc.$172M#7—1.0x#53.2x#4110.5%#169.1%#3-104.0%#2-29.0%#5————
STROSUTRO BIOPHARMA, INC.$157M#9——1.5x#165.2%#215.9%#5-154.5%#4—————
TARAProtara Therapeutics, Inc.$144M#10—0.9x#448.7x#8—-28.7%#8-2189.6%#8-35.6%#7——-52.4%#7—
CMPXCompass Therapeutics, Inc.$138M#11—0.8x#3—-100.0%#7-34.7%#9—-40.0%#9——-79.5%#10—
CHRSCoherus Oncology, Inc.$124M#12—2.0x#83.0x#359.8%#3489.4%#1-429.5%#7276.2%#1-351.2%#4—-49.3%#6—
HUMAHumacyte, Inc.$122M#13—3.9x#1259.7x#9—72.5%#2-5306.0%#10-130.6%#12——-72.4%#9—
ARMP$114M#14————-818.8%#16—————0.1%#1
VYGRVoyager Therapeutics, Inc.$113M#15—0.7x#22.8x#2-49.5%#5-84.2%#12-326.6%#6-77.6%#10——-59.9%#8—
OTLK$112M#16——79.3x#10—17.2%#4-4744.3%#9—-12.8%#2———

Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.

Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice

LIMN's peers

PALIPLXIKTARTVDTILACOGIVVDSTROTARACMPXCHRSHUMAARMPVYGROTLK
← LIMN overview